Current pharmacological treatment of hepatocellular carcinoma

Bruix, 2019, Insights into the success and failure of systemic therapy for hepatocellular carcinoma, Nat Rev Gastroenterol Hepatol, 16, 617, 10.1038/s41575-019-0179-x Bruix, 2021, Systemic treatment of hepatocellular carcinoma: an EASL position paper, J Hepatol, 10.1016/j.jhep.2021.07.004 Gordan, 2020, Systemic therapy for advanced hepatocellula carcinoma: ASCO guideline, J Clin Oncol, 38, 4317, 10.1200/JCO.20.02672 Vogel, 2021, Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines, Ann Oncol, 10.1016/j.annonc.2021.02.014 Reig, 2021, Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH, Med Clin (Barc), 156, 463.e1, 10.1016/j.medcli.2020.09.022 Bruix, 2021, Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: an unresolved Gordian knot, J Hepatol, 74, 1483, 10.1016/j.jhep.2021.01.033 Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056/NEJMoa1915745 Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9 Abou-Alfa, 2018, Cabozantinib in patients with advanced and progressing hepatocellular carcinoma, N Engl J Med, 379, 54, 10.1056/NEJMoa1717002 Zhu, 2019, Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 282, 10.1016/S1470-2045(18)30937-9 Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1 Merchante, 2017, Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients, AIDS, 31, 89, 10.1097/QAD.0000000000001293 Díaz-González, 2020, International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis, Liver Int, 40, 1467, 10.1111/liv.14436 Mancuso, 2015, Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis, Dig Liver Dis, 47, 324, 10.1016/j.dld.2015.01.001 Invernizzi, 2020, Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation, Transplantation, 104, 568, 10.1097/TP.0000000000002955 Iavarone, 2019, Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation, Am J Transplant, 19, 3176, 10.1111/ajt.15551 Marrero, 2016, Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study, J Hepatol, 65, 1140, 10.1016/j.jhep.2016.07.020 Leal, 2018, Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study, Invest N Drugs, 36, 911, 10.1007/s10637-018-0621-x Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7 Rimola, 2020, Radiological response to nivolumab in patients with hepatocellular carcinoma: a multicenter analysis of real-life practice, Eur J Radiol Reig, 2020, Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab, Liver Int Reig, 2013, Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design, Hepatology, 58, 2023, 10.1002/hep.26586 Rimassa, 2018, Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study, Lancet Oncol, 19, 682, 10.1016/S1470-2045(18)30146-3 Iavarone, 2015, Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib, Hepatology, 62, 784, 10.1002/hep.27729 Ogasawara, 2016, Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib, Invest N Drugs, 34, 255, 10.1007/s10637-016-0323-1 Cao, 2011, Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model, Lab Invest, 91, 598, 10.1038/labinvest.2010.205 Cabrera, 2013, Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma, Cancer Immunol Immunother, 62, 737, 10.1007/s00262-012-1380-8 Ou, 2021, Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages, J Immunother Canc, 9 Chen, 2015, CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice, Hepatology, 61, 1591, 10.1002/hep.27665 Tang, 2020, The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects, Signal Transduct Target Ther, 5, 1 Corominas, 2021, Activated lymphocytes and increased risk of dermatologic adverse events during sorafenib therapy for hepatocellular carcinoma, Cancers (Basel), 13, 1, 10.3390/cancers13030426 Forner, 2018, Hepatocellular carcinoma, Lancet, 391, 1301, 10.1016/S0140-6736(18)30010-2 Iavarone, 2011, Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy, Hepatology, 54, 2055, 10.1002/hep.24644 Reig, 2014, Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib, J Hepatol, 61, 318, 10.1016/j.jhep.2014.03.030 Finn, 2020, Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial, J Clin Oncol, 38, 193, 10.1200/JCO.19.01307 Bruix, 2015, Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet Oncol, 16, 1344, 10.1016/S1470-2045(15)00198-9 Ricke, 2019, Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma, J Hepatol, 71, 1164, 10.1016/j.jhep.2019.08.006 Vilgrain, 2017, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016/S1470-2045(17)30683-6 Kudo, 2014, Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial, Hepatology, 60, 1697, 10.1002/hep.27290 Lencioni, 2016, Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial, J Hepatol, 64, 1090, 10.1016/j.jhep.2016.01.012 Meyer, 2017, Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial, Lancet Gastroenterol Hepatol, 2, 565, 10.1016/S2468-1253(17)30156-5